HC Wainwright Reiterates Buy Rating for Oruka Therapeutics (NASDAQ:ORKA)

HC Wainwright reissued their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a report released on Monday morning,Benzinga reports. The brokerage currently has a $45.00 price objective on the stock. HC Wainwright also issued estimates for Oruka Therapeutics’ Q3 2025 earnings at ($0.54) EPS, FY2025 earnings at ($2.23) EPS, Q2 2026 earnings at ($0.68) EPS and FY2026 earnings at ($2.77) EPS.

A number of other brokerages also recently issued reports on ORKA. Wedbush reissued an “outperform” rating and issued a $40.00 price target on shares of Oruka Therapeutics in a report on Tuesday, August 12th. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 16th. Finally, BTIG Research initiated coverage on shares of Oruka Therapeutics in a report on Thursday, May 22nd. They issued a “buy” rating on the stock. Two analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $40.38.

Oruka Therapeutics Stock Down 1.1%

NASDAQ ORKA opened at $14.40 on Monday. The company has a market cap of $539.28 million, a PE ratio of -5.12 and a beta of -0.35. Oruka Therapeutics has a 52 week low of $5.49 and a 52 week high of $52.32. The firm’s 50-day simple moving average is $13.47 and its two-hundred day simple moving average is $11.57.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.02. As a group, equities research analysts anticipate that Oruka Therapeutics will post -3.41 EPS for the current year.

Institutional Investors Weigh In On Oruka Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ORKA. Price T Rowe Associates Inc. MD raised its stake in Oruka Therapeutics by 374.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,326,893 shares of the company’s stock valued at $25,730,000 after purchasing an additional 1,047,245 shares in the last quarter. Braidwell LP raised its stake in Oruka Therapeutics by 122.5% in the fourth quarter. Braidwell LP now owns 1,147,676 shares of the company’s stock valued at $22,253,000 after purchasing an additional 631,950 shares in the last quarter. Janus Henderson Group PLC raised its stake in Oruka Therapeutics by 259.7% in the fourth quarter. Janus Henderson Group PLC now owns 849,410 shares of the company’s stock valued at $16,415,000 after purchasing an additional 613,294 shares in the last quarter. Polar Capital Holdings Plc purchased a new stake in Oruka Therapeutics in the fourth quarter valued at approximately $10,664,000. Finally, Geode Capital Management LLC raised its stake in Oruka Therapeutics by 100.6% in the second quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock valued at $7,932,000 after purchasing an additional 354,821 shares in the last quarter. 56.44% of the stock is owned by hedge funds and other institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.